Research and Clinical Studies of Apligraf(R) Bilayered Living Cellular Construct Presented at SAWC / WHS 2010 Meeting

Monday, April 19, 2010 Research News
Email Print This Page Comment bookmark
Font : A-A+

CANTON, Mass. and ORLANDO, Fla., April 18 Organogenesis, Inc. will have a substantial presence at the 23rd Annual Symposium on Advanced Wound Care and Wound Healing Society (SAWC / WHS 2010) being held April 17-20 in Orlando, FL. Results from several clinical and scientific studies will be presented which will further the understanding of Organogenesis' bilayered living cellular construct technology. The company is also showcasing its flagship product Apligraf® (booth 417) as well as hosting events during the annual conference.

The clinical studies presented at WHS / SAWC 2010 help to further delineate the safety and efficacy of Apligraf for the treatment of diabetic foot ulcers and venous leg ulcers. "Although the wounds in these clinical trials were of varying sizes and different etiologies, Apligraf consistently accelerated the rate of healing in these challenging chronic wounds," explained author of the clinical reviews and Organogenesis Chief Medical Officer Damien Bates, M.D., Ph. D., F.R.A.C.S. (Plast.).

Apligraf is a living cell based product used by physicians to heal patients with diabetic foot ulcers and venous leg ulcers in the U.S. and around the world. It was the first bioengineered cell based product to receive FDA approval for chronic wounds. Venous leg ulcers and diabetic foot ulcers are open wounds that, for a variety of reasons, fail to heal by the body's own systems. They are amongst the most frequently occurring chronic wounds, affecting more than three million people every year in the United States alone.

The company's ongoing research and development efforts have produced valuable information regarding the characterization of skin cell markers, the development of in vitro and in vivo models to further study the process of wound healing and to translate research discoveries into tissue-engineered products. These presentations reemphasize the company's proven ability to bridge the gap between research, manufacturing and delivering product to treat patients.

"The ten clinical and scientific presentations at SAWC / WHS 2010 reflect the efforts of many researchers within the company, and reinforce the leadership of Organogenesis in the field of regenerative medicine," continued Dr. Bates.

In addition to the papers presented, Organogenesis is also showcasing Apligraf at booth 417 and sponsoring multiple events during the annual meeting. The company has provided an educational grant to sponsor the WHS General Session, "Approaches for Tissue Repair: Promoting Tissue Engineering and Minimizing Scarring," featuring keynote speaker Michael Longaker, MD; and has sponsored a breakfast session, "The Role of Keratinocytes and Fibroblasts in Wound Healing: Bringing the Science to Your Practice," featuring Reynald Allam, MD, Vincent Ronfard, PhD and Kara Couch, MS, CRNP, CWS.

About Apligraf®

Apligraf® contains two layers of human living cells: an outer protective layer of differentiated keratinocytes and an inner layer of fibroblasts in a collagen matrix. When placed on a wound previously unresponsive to treatment, Apligraf provides cells, collagen matrix and other proteins that provide a covering that has been demonstrated to promote healing. In multiple controlled clinical studies, Apligraf has been shown to be an effective and safe wound care treatment, superior to conventional treatments. Over 300,000 units of Apligraf have been shipped by Organogenesis for patient applications, and the product is covered extensively by Medicare, Medicaid and by 350 private payers in the U.S.

About Organogenesis, Inc.

Having pioneered the field, Massachusetts based Organogenesis, Inc. is a leading regenerative medicine company focused in the areas of bioactive wound healing, oral regeneration and biosurgery. The company's mission is to bring the medical marvel of regenerative medicine products to patients and to standardize their use in everyday medical care. Organogenesis recently established European headquarters located in Switzerland, as well as announced an expansion of its U.S. headquarters. For more information, visit

SOURCE Organogenesis, Inc.

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store